Mansour Lab:Journal Publications

Journal Publications

== 2001-2009 ==

1. Mansour H., Wang D.-S., Chen C.-S., and Zografi G. Comparison of Bilayer and Monolayer Properties of Phospholipid Systems Containing Dipalmitoylphosphatidylglycerol and Dipalmitoylphosphatidylinositol. Langmuir (2001) 17 (21) October 16: 6622-6632. (Impact Factor: 4.384)[1]

2. Mansour, H.M. and Zografi G. The Relationship Between Water Vapor Absorption and Desorption by Phospholipids and Bilayer Phase Transitions. Journal of Pharmaceutical Sciences (2007) 96 (2) February: 377-396. (Impact Factor: 3.007)[2]

3. Mansour, H.M. and Zografi G. Relationships Between Equilibrium Spreading Pressure and Phase Equilibria of Phospholipid Bilayers and Monolayers at the Air-Water Interface. Langmuir (2007) 23 (7) March 27: 3809-3819. (Impact Factor: 4.384)[3]

4. Hickey, A.J., Mansour, H.M., et al. Physical Characterization of Component Particles Included in Dry Powder Inhalers: I. Strategy Review and Static Characteristics. Journal of Pharmaceutical Sciences: Special Issue David Grant Dedicated Issue (2007) 96 (5) May: 1282-1301. (Impact Factor: 3.007)[4]

5. Hickey, A.J., Mansour, H.M., et al. Physical Characterization of Component Particles Included in Dry Powder Inhalers: II. Dynamic Characteristics. Journal of Pharmaceutical Sciences: Special Issue David Grant Dedicated Issue (2007) 96 (5) May: 1302-1319. (Impact Factor: 3.007)[5]

6. Mansour, H.M. and Hickey, A.J. Raman Characterization and Chemical Imaging of Biocolloidal Self-Assemblies, Drug Delivery Systems, and Pulmonary Inhalation Aerosols. A Review. AAPS PharmSciTech (2007) 8 (4) November 30: Article 99:E1-E16. (Impact Factor: 1.776)[6]

7. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Comparative Dispersion Study of Dry Powder Aerosols of Albuterol Sulfate/Lactose Monohydrate and Cromolyn Sodium/Lactose Monohydrate Delivered by Standardized Entrainment Tubes. Respiratory Drug Delivery (2008) 3: 897-900. [7]

8. Mansour H.M., Damodaran S., and Zografi G. Characterization of the In Situ Structural and Interfacial Properties of the Cationic Hydrophobic Heteropolypeptide, KL4, in Lung Surfactant Bilayer and Monolayer Models at the Air-Water Interface: Implications for Pulmonary Surfactant Delivery. Molecular Pharmaceutics (2008) 5 (5) October 6: 681-695. (Impact Factor: 4.787)[8]

9. Mansour, H.M., Rhee, Y.S., and Wu, X. Nanomedicine in Pulmonary Delivery. International Journal of Nanomedicine (2009) 4 December: 299-319.(Impact Factor: 4.195)[9]

== 2010 ==

10. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Drug Blends with Lactose Monohydrate: 1. Albuterol Sulfate and Disodium Cromoglycate. Journal of Pharmaceutical Sciences (2010) 99 (8) March 2: 3398-3414.(Impact Factor: 3.007)[10]

11. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Drug Blends with Lactose Monohydrate: 2. Ipratropium Bromide Monohydrate and Fluticasone Propionate. Journal of Pharmaceutical Sciences (2010) 99 (8) March 10: 3415-3429. (Impact Factor: 3.007)[11]

12. Mansour, H.M., Xu, Z., and Hickey, A.J. Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Alternative Sugar Blends: 3. Trehalose Dihydrate and D-Mannitol Carriers. Journal of Pharmaceutical Sciences (2010) 99 (8) March12; 3430-3441.(Impact Factor: 3.007)[12]

13. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Heterogenous Particle Deaggregation and Its Implications for Therapeutic Aerosol Performance. Journal of Pharmaceutical Sciences (2010) 99 (8) March 15: 3442-3461.(Impact Factor: 3.007)[13]

14. Mansour, H.M., Sohn, M., Al-Ghananeem, A., and DeLuca P.P. Materials for Pharmaceutical Dosage Forms: Molecular Pharmaceutics and Controlled Release Drug Delivery Aspects. Invited Paper. International Journal of Molecular Sciences: Special Issue-Material Sciences and Nanotechnology Section - Biodegradability of Materials in Biomedical Applications. (2010) 11: 3298-3322. (Impact Factor: 2.339)[14]

15. Rhee, Y.S., Park, C.W., DeLuca, P.P., and Mansour, H.M. Sustained-Release Injectable Drug Delivery Systems. An Invited Paper. Pharmaceutical Technology: Special Issue-Drug Delivery (2010) November: 6-13. [15]

16. Hayes, D. Jr., Zwischenberger, J.B., and Mansour, H.M. Aerosolized Tacrolimus: A Case Report in a Lung Transplant Recipient. Transplantation Proceedings (2010) 42 (9) November: 3876-3879.(Impact Factor: 1.061) [16]

17. Wu, X., Li, X., and Mansour, H.M. Surface Analytical Techniques in Solid-State Particle Characterization: Implications for Predicting Performance in Dry Powder Inhalers. Invited Paper. KONA Powder and Particle Journal (2010) 28: 3-19/ (Impact Factor: 1.227) [17]

== 2011 ==

18. Xu, Z., Mansour, H.M., and Hickey, A.J. Particle Interactions in Dry Powder Inhaler Unit Processes. Journal of Adhesion Science and Technology: Special Issue on Adhesion Aspects in Pharmaceutical Sciences (2011): 25 (4/5) 451-482. (Impact Factor: 1.175)[18]

19. Rhee, Y.S. and Mansour, H.M. Nanopharmaceuticals I: Nanocarrier Systems in Drug Delivery. Invited Paper. International Journal of Nanotechnology: Special Issue-Nanopharmaceuticals. (2011) 8 (1/2): 84-114.(Impact Factor: 1.144)[19]

20. Wu, X. and Mansour, H.M. Nanopharmaceuticals II: Application of Nanoparticles and Nanocarrier Systems in Pharmaceutics and Nanomedicine. Invited Paper. International Journal of Nanotechnology: Special Issue-Nanopharmaceuticals. (2011) 8 (1/2): 115-145. (Impact Factor: 1.144)[20]

21. Wu, X.,and Mansour, H.M. Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems. Invited Paper. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry: Special Issue-Optimizing a Therapeutic with Anti-Inflammatory Agents: Novel Drug Delivery Systems. (2011)10 (3): 215-229. [21]

22. Park, C.W., Hayes, D. Jr., and Mansour, H.M. Pulmonary Inhalation Aerosols for Targeted Antibiotics Drug Delivery. Invited Paper & Cover Page. European Pharmaceutical Review. (2011) 16 (1): 32-36.[22]

23. Mansour, H.M. Molecular Forces and Self Assembly in Colloid, Nano Sciences and Biology. Invited Paper. Journal of the American Chemical Society. (2011) 133 (13): 5162. (Impact Factor: 9.907) [23]

24. Hayes, D. Jr and Mansour, H.M. Improved Outcomes of Patients with End-Stage Cystic Fibrosis Requiring Invasive Mechanical Ventilation for Acute Respiratory Failure. Lung. (2011) 189 (5): 409-415. (Impact Factor: 2.171)[24] [25]

25. Hayes, D. Jr., Ball, A.M., Mansour, H.M., Martin, C.A.,and Flynn, J.D. Fungal Infection in Heart-Lung Transplant Recipients Receiving Single-agent Prophylaxis With Itraconazole. Experimental and Clinical Transplantation (2011)9 (6): 399-404. [26].

26. Rhee, Y.S., Sohn, M., Woo, B.H., Thanoo, B.C., DeLuca, P.P., and Mansour, H.M. Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres. AAPS PharmSciTech: Special Theme Issue-Sterile Products: Advances and Challenges in Formulation, Manufacturing, Devices and Regulatory Aspects.(2011)12 (4):1293-1301. (Impact Factor: 1.776)[27] [28]

27. Li, X. and Mansour, H.M. Physicochemical Characterization and Water Vapor Absorption of Organic Solution Advanced Spray Dried Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery. AAPS PharmSciTech: Special Theme Issue: Advances in Pharmaceutical Excipients Research and Use: Novel Materials, Functionalities and Testing (2011)12(4):1420-1430. (Impact Factor: 1.776)[29] [30]

== 2012 ==

28. Hayes, D. Jr., Winkler, M.A., Kirkby, S., Capasso, P., Mansour, H.M. and Attili, A.K. Preprocedural Planning with Prospectively Triggered Multi-Detector Row CT Angiography prior to Bronchial Artery Embolization in Cystic Fibrosis Patients with Massive Hemoptysis. Lung (2012)190 (2)April:221-225.(Impact Factor: 2.171)[31]

29. Hayes, D. Jr. and Mansour, H.M. Vanishing Bronchus Intermedius Syndrome in a Pediatric Patient with Cystic Fibrosis After Lung Transplantation. Pediatric Transplantation: The Official Journal of the International Pediatric Transplant Association (2012)16(8):333-337. [Impact Factor: 1.630][32]

30. Hayes, D. Jr., Mansour, H.M., Kirkby, S., and Phillips, A.B. Rapid Acute Onset of Bronchiolitis Obliterans Syndrome in a Lung Transplant Recipient After Respiratory Syncytial Virus Infection." Transplant Infectious Diseases (2012)14 (5): 548-550. [Impact Factor: 2.25][33]

31. Duan, J.H., Mansour, H.M., Zhang, Y.D., Deng, X.M., Zhao, J.F. Reversion of Multi-Drug Resistance by Co-Encapsulation of Doxorubicin and Curcumin in Chitosan/poly(butylcyanoacrylate) Nanoparticles. International Journal of Pharmaceutics (2012) 426 (1-2): 193-201. (Impact Factor: 3.785)[34]

32. Park, C.W., Mansour, H.M., Oh, T.O., Kim, J.Y., Ha, J.M., Lee, B.J., Chi, S.C., Rhee, Y.S., Park, E,S. "Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications." International Journal of Pharmaceutics (2012) 436 (1-2):652-658.(Impact Factor: 3.785) [35]

33. Park, C.W., Rhee, Y.S., Vogt, F.G., Hayes, D Jr., Zwischenberger, J.B., DeLuca, P.P., and Mansour, H.M. Advances in Microscopy and Complementary Imaging Techniques to Assess the Fate of Drugs Ex-Vivo in Respiratory Drug Delivery. Invited Paper. Advanced Drug Delivery Reviews: Special Theme Issue-Computational and Visualization Approaches in Respiratory Delivery. (2012) 64 (4) March 30: 344-356. (Impact Factor: 12.707)[36]

34. Willis, M.L., Hayes, D Jr., and Mansour, H.M. Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. Lung (2012) 190 (3): 251-262.(Impact Factor: 2.171)[37] [38]

35.Mansour, H.M. "Aerosol Formulation Issues." Pediatric Pulmonology (2012) 47 (35):149-151. (Impact Factor: 2.297) [39]

== 2013 ==

36. Meenach, S.A. Vogt,F.G., Anderson, K.W., Hilt, J.Z., McGarry,R.C., and Mansour, H.M.. Design, Physicochemical Characterization, and Optimization of Organic Solution Advanced Spray-Dried Inhalable Dipalmitoylphosphatidylcholine (DPPC) and Dipalmitoylphosphatidylethanolamine Poly(Ethylene Glycol) (DPPE-PEG) Microparticles and Nanoparticles for Targeted Respiratory Nanomedicine Delivery as Dry Powder Inhalation Aerosols. International Journal of Nanomedicine (2013) 8:275-293.(Impact Factor: 4.195)[40]

37. Meenach, S.A., Anderson, K.W., Hilt, J.Z., McGarry, R.C., and Mansour, H.M. Characterization and Aerosol Dispersion Performance of Advanced Spray-Dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer. European Journal of Pharmaceutical Sciences (2013) 49 (4): 699-711.(Impact Factor: 3.005)[41]

38. Wu,X., Hayes, D Jr., Zwischenberger, J.B., Kuhn, R.J., and Mansour, H.M. Design and Physicochemical Characterization of Advanced Spray-Dried Tacrolimus Multifunctional Particles for Inhalation. Drug Design, Development, and Therapy (2013) 7:59-72. (Impact Factor: 3.026) [42]

39. Wu,X., Zhang, W., Hayes, D Jr., and Mansour, H.M. Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Cyclosporine A Multifunctional Particles for Dry Powder Inhalation Aerosol Delivery. International Journal of Nanomedicine (2013) 8 :1269-1283.(Impact Factor: 4.195)[43]

40. Park, C.W., Li X., Vogt, F.G., Hayes, D. Jr., Zwischenberger, J.B., Park, E.S. and Mansour, H.M. Advanced Spray Dried Design, Physicochemical Characterization and Aerosol Dispersion Performance of Vancomycin and Clarithromycin Multifunctional Controlled Release Particles for Targeted Respiratory Delivery as Dry Powder Inhalation Aerosols.. International Journal of Pharmaceutics (2013) 455 (1–2): 374–392.(Impact Factor: 3.785)[44]

41. Zheng Z, Zhang W, Sun W, Li X, Duan J, Cui J, Feng Z, and Mansour, H.M. Influence of the Carboxymethyl Chitosan Anti-Adhesion Solution on the TGF-β1 in a Postoperative Peritoneal Adhesion Rat. Journal of Materials Science: Materials in Medicine (2013) 24 (11): 2549-2559. (Impact Factor: 2.379) [45]

42. Duan J.H., Vogt, F.G., Li X., Hayes, D. Jr., and Mansour, H.M. Design, Physicochemical Characterization and Aerosolization of Organic Solution Advanced Spray Dried and Co-Spray Dried Moxifloxacin and Ofloxacin Dipalmitoylphosphatidylcholine (DPPC) Microparticulate/Nanoparticulate Powders for Pulmonary Inhalation Aerosol Delivery. International Journal of Nanomedicine (2013) 8: 3489-3505. [46](Impact Factor: 4.195)

43. Hayes, D. Jr., Galantowicz, M., Yates, A.R., Preston, T.J., Mansour, H.M., and McConnell, P.I. Venovenous ECMO as a Bridge to Lung Transplant and Protective Strategy for Subsequent Primary Graft Dysfunction. Journal of Artificial Organs (2013) 16 (3): 382-385. (Impact Factor: 1.60)[47]

44. Hayes, D. Jr., Baker, P.B., Mansour, H.M., Peeples, M.E., and Nicol, K.K. Interstitial Lung Disease in a Child with Antisynthetase Syndrome. Lung (2013) 191 (4): 441-443. (Impact Factor: 2.171)[48]

45.Hayes, D. Jr., Daniels, C.J., Mansour, H.M., Kopp, B.T., Yates, A.R., McCoy, K.S., Patel, A.V., and Kirby, S. Right Heart Catherization Measuring Central Hemodynamics in Cystic Fibrosis During Exercise. Respiratory Medicine (2013): 107 (9): 1365–1369. [Impact Factor: 2.917][49]

46. Hayes, D. Jr., Daniels, C.J., Mansour, H.M., Kopp, B.T., Yates, A.R., Preston, T., and Kirby, S. Identification of the Nodose Ganglia and TRPV1 in Swine. Lung (2013): 191(5):445-447(Impact Factor: 2.171)[50]

47.Hayes, D Jr., Kirkby, S., McCoy, K.S., Mansour, H.M., Khosravi, M., Strawbridge, H., and Tobias, J.D. Reduction of Lipid-Laden Macrophage Index After Laproscopic Nissen Fundoplication in Cystic Fibrosis Patients After Lung Transplantation. Clinical Transplantation (2013) 27 (1): 121-125.(Impact Factor: 1.486) [51]

== 2014 ==

48. Hayes, D. Jr., Yates, A.R., Duffy, V., Tobias, J., Mansour, H.M., Olshove, V., and Preston, T.J. Rapid placement of bicaval dual-lumen catheter in a swine model of venovenous ECMO. Journal of Investigative Surgery (2014): 27(1):27-31. [Impact Factor: 1.316] [52]

49. Hayes, D. Jr., Adler, B., Turner, T.L., and Mansour, H.M.. Alternative Tacrolimus and Sirolimus Regimen Associated with Rapid Resolution of Posterior Reversible Encephalopathy Syndrome After Lung Transplantation. Pediatric Neurology (2014) 50: 272-275.(Impact Factor: 1.504)[53]

50. Li X., Vogt, F.G., Hayes, D. Jr., and Mansour, H.M. Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray Dried Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and Azithromycin for Pulmonary Inhalation Aerosol Delivery. European Journal of Pharmaceutical Sciences (2014) 15: 191-205. (Impact Factor: 3.005) [54]

51.Li X., Vogt, F.G., Hayes, D. Jr., and Mansour, H.M. Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. Journal of Aerosol Medicine & Pulmonary Drug Delivery (2014): 27 (2):81-93. (Impact Factor: 2.395)[55]

52. Li X., Vogt, F.G., Hayes, D. Jr., and Mansour, H.M. Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Co-Spray Dried Antibiotics with Mannitol as Respirable Microparticles/Nanoparticles for Targeted Pulmonary Delivery as Dry Powder Inhalers. Journal of Pharmaceutical Sciences: George Zografi Dedicated Issue (2014)103(9): 2937-2949. [Impact Factor: 3.007][56]

53. Muralidharan, P., Mallory, E., Malapit, M., Hayes, D. Jr., and Mansour, H.M. Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Pharmaceutics: Special Issue: Liposomal Technologies (Guest Editor: Prof. Timothy D. Heath, UW-Madison) (2014) 6 (2): 333-353. [57] [58]

54. Meenach, S.A., Anderson, K.W., Hilt, J.Z., McGarry, R.C., and Mansour, H.M. High-Performing Dry Powder Inhalers of Paclitaxel DPPC/DPPG Lung Surfactant-Mimic Multifunctional Particles in Lung Cancer: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. AAPS PharmSciTech: Theme Issue on Advances in Formulation and Device Technologies in Pulmonary Drug Delivery (2014) IN PRESS. [Impact Factor: 1.776] [59] [60]

55. Hayes, D. Jr., McCoy, K.S., Whitson, B.A., Mansour, H.M., and Tobias, J.D. High-Risk Age Window for Mortality in Children with Cystic Fbrosis After Lung Transplantation. Pediatric Transplantation (2014) IN PRESS. [Impact Factor: 1.63] [61]

56. Hayes, D. Jr., Tobias, J.D., Mansour, H.M., Kirkby, S., McCoy, K.S., Daniels, C.J., and Whitson, B.A. Pulmonary Hypertension in Cystic Fibrosis with Advanced Lung Disease. American Journal of Respiratory and Critical Care Medicine (2014) IN PRESS. [Impact Factor: 11.986] [62]
“F1000Prime Recommended by F1000Respiratory Disorders Faculty” [63]

57. Muralidharan, P., Hayes, D. Jr., and Mansour, H.M. Dry Powder Inhalers in COPD, Lung Inflammation, and Pulmonary Infections. Expert Opinion on Drug Delivery: Theme Issue on Drug Delivery to the Lungs (2014) IN PRESS (Impact Factor: 4.116)[64]